Edwards Lifesciences Reports Second Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Kroger (KR) To Cut Corporate Workforce By About 3,000 Over 3 Years - Bloomberg
- Sysco calls on Teamsters to end LA strike after economic deal reached
Edwards Lifesciences (EW) PT Raised to $120 at Oppenheimer
July 30, 2021 6:27 AM EDTOppenheimer analyst Suraj Kalia raised the price target on Edwards Lifesciences (NYSE: EW) to $120.00 (from $97.00) while maintaining an Outperform rating.
The analyst commented, "Edwards reported 2Q21 revenues of $1.38B vs. our/consensus' $1.29B/$1.28B estimates and guidance of $1.251.33B. TAVR revenues... More
Edwards Lifesciences (EW) Tops Q2 EPS by 9c; Raises Outlook
July 29, 2021 4:20 PM EDTEdwards Lifesciences (NYSE: EW) reported Q2 EPS of $0.64, $0.09 better than the analyst estimate of $0.55. Revenue for the quarter came in at $1.4 billion versus the consensus estimate of $1.28 billion.
GUIDANCE:
Edwards Lifesciences sees FY2021 EPS of $2.07-$2.27, versus the consensus of $2.21.... More



